Jonathan Aschoff
Stock Analyst at Roth Capital
(0.48)
# 4,097
Out of 5,012 analysts
38
Total ratings
24.49%
Success rate
-36.59%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $1.19 | +824.37% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $10.52 | +99.71% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.70 | +349,162.54% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.69 | +965.09% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $3.82 | +18,591.10% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.56 | +3,447.99% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.50 | +7,892.01% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $4.99 | +16,733.67% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $12.86 | +180.05% | 1 | Mar 7, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $18.41 | +97,672.95% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $7.68 | +290.63% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $9.41 | +2,025.83% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.62 | +434.35% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $1.63 | +1,325,053.37% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.87 | +328.95% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.50 | +2,757.14% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.03 | +38,738.72% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $8.97 | +323.87% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.60 | +3,592.31% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.01 | +548.38% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $1.19
Upside: +824.37%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $10.52
Upside: +99.71%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.70
Upside: +349,162.54%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.69
Upside: +965.09%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $3.82
Upside: +18,591.10%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.56
Upside: +3,447.99%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.50
Upside: +7,892.01%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $4.99
Upside: +16,733.67%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $12.86
Upside: +180.05%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $18.41
Upside: +97,672.95%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $7.68
Upside: +290.63%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $9.41
Upside: +2,025.83%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.62
Upside: +434.35%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $1.63
Upside: +1,325,053.37%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.87
Upside: +328.95%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $3.50
Upside: +2,757.14%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.03
Upside: +38,738.72%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $8.97
Upside: +323.87%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.60
Upside: +3,592.31%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.01
Upside: +548.38%